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Abstract
Background: Risk factors for congenital cryptorchidism were investigated in a prospective birth cohort study in Denmark
and Finland from 1997 to 2001.
Methodology and Principal Findings: In total, 2,496 boys were examined for cryptorchidism at birth (cryptorchid/healthy:
128/2,368) and three months old (33/2,215). Information on risk factors was obtained antenatally (questionnaire/interview)
or at birth from birth records. Use of nicotine substitutes during pregnancy (n=40) and infertility treatment by intrauterine
insemination (n=49) were associated with an increased risk for cryptorchidism, adjusted odds ratio (95% confidence
interval) (OR (95%CI)) 3.04 (95%CI 1.00–9.27) and 3.01 (95%CI 1.27–7.15), respectively. No association was seen for mothers
(n=79) who had infertility treatment in form of intracytoplasmic sperm injection (ICSI) or in vitro fertilization (IVF) treatment
(OR 0.71 95%CI 0.21–2.38). In total, 728 (29%) reported to have smoked during pregnancy, however, no increased risk
among maternal smokers was found. Furthermore, we found statistically significant associations between cryptorchidism
and low birth weight, prematurity, being small for gestational age, substantial vaginal bleeding, and breech presentation,
which are in accordance with other studies.
Conclusions and Significance: Our study revealed two novel risk factors for cryptorchidism: intrauterine insemination and
the use of nicotine substitutes in pregnancy. This suggests that cryptorchidism may not only be associated to genetic
factors, but also to maternal lifestyle and exposure.
Citation: Damgaard IN, Jensen TK, Petersen JH, Skakkebæk NE, Toppari J, et al. (2008) Risk Factors for Congenital Cryptorchidism in a Prospective Birth Cohort
Study. PLoS ONE 3(8): e3051. doi:10.1371/journal.pone.0003051
Editor: Jacqueline Ho, JARING, Malaysia
Received May 9, 2008; Accepted August 4, 2008; Published August 25, 2008
Copyright:  2008 Damgaard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by The University of Copenhagen, The Danish Medical Research Council (no. 9700833 and 9700909), Svend Andersens
Foundation, Novo Nordisk Foundation, The Academy of Finland, Sigrid Juse ´lius Foundation, Turku University Central Hospital and the European Commission
(contracts BMH4-CT96-0314, QLK4-CT1999-01422, QLK4-2001-00269 and QLK4-CT2002-00603). The Danish National Research Foundation has established the
Danish Epidemiology Science Center that initiated and created the DNBC. The cohort is furthermore a result of a major grant from this foundation. Additional
support for the DNBC is obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus
Foundation and the Health Foundation. The authors are solely responsible for the contents of the manuscript. The sponsors had no part in the study neither in
design, data collection, analysis nor in interpretation or in writing the paper. The European Community received annual reports concerning the progression of the
study but is not responsible for any use that may be made of data appearing therein.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ind@rh.dk
Introduction
Cryptorchidism is the most common congenital genital
malformation in males. In the Western countries, the condition
is estimated to occur in 2–5% of full-term newborn boys [1]. Most
cases appear isolated without other malformations, and only very
few are part of genetic or endocrine syndromes. Cryptorchidism is
the best described risk factor for testicular cancer [2,3]. In some
cases, defects in specific genes, e.g. INSL3 seem to be involved [4],
but although a variety of risk factors have been reported, e.g. low
birth weight, prematurity, low parity and twinning [5–8], the
aetiology remains largely unknown. Several studies indicate an
increase in the prevalence of congenital cryptorchidism within a
few generations supporting the hypothesis that lifestyle changes
and environmental factors may be involved [9–12].
Normal testicular development and descent in humans is strongly
dependent on normal sex hormone balance [1] and may thus be
sensitive to adverse environmental and lifestyle exposures not only in
the first trimester but throughout the entire pregnancy.
Most previous studies of risk factors for cryptorchidism have
included data obtained retrospectively by either self-administered
questionnaires or interviews conducted post partum [13–19]. These
studies may therefore be compromised by recall and selection bias.
Furthermore,severalstudieshavebeenbased onregistrydata,which
may be hampered by variations in ascertainment of the diagnosis
and reporting strategies [20]. To overcome this, we conducted a
prospective, population-based cohort study of pregnant women and
their newborn boys, in which information on risk factors was
obtained antenatally and from birth records at birth and in which all
includedboyswereexaminedunderstandardisedconditionsinorder
to ensure a valid diagnosis.
We have previously described an association between maternal
alcohol consumption during pregnancy and cryptorchidism in this
cohort [21]. We have earlier also shown an association of an
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[10]. In this study, we investigated additional infant, maternal and
delivery characteristics associated with cryptorchidism.
Methods
We performed a prospective birth cohort study at the University
Hospital of Copenhagen (Rigshospitalet and Hvidovre Hospital) in
Denmark from 1997 to 2001 and at the Turku University Central
Hospital in Finland in the period 1997–99. Eligible women (2,229
Danish and 2,728 Finnish) residing in the hospital referral areas
were consecutively recruited during early pregnancy. In Denmark,
eligible families (selected on Danish surname) were contacted by
mail. In Finland, the women were recruited on their first visit at
the antenatal clinics. Women referred from outside the recruit-
ment area because of pregnancy complications were excluded. In
order to obtain genetically and environmentally well-defined
populations, only families who met the following criteria were
included: both parents and grandparents of the unborn child had
to be born and raised in Denmark, or respectively in Finland. A
maximum residence abroad of three years for the mother and ten
years for the father and grandparents was allowed.
Of 4,957 women initially included 2,639 gave birth to 2,666
boys. A total of 95 families (including 5 pairs of boy–boy twins)
dropped out before the first examination (4 moved, 44
uninterested, 3 child dead, 7 child sickness, 30 lost, 7 other
reasons). Furthermore, 58 boys were not examined at birth, 8 were
not included due to a missing questionnaire and 4 were excluded
for other reasons (1 unilateral torsion, 1 unilateral agenesis, 2 could
not be classified at birth due to severe bilateral hernia) [21].
The study was conducted in two different countries and
therefore questionnaires, interviews and examinations were strictly
standardized. The families were included in early pregnancy after
written informed consent. The participating women received a
self-administered questionnaire late in 1st trimester or early in 2nd
trimester covering education and occupation, maternal pre-
pregnancy weight and height, medical and obstetric history. All
women were asked about infertility treatment (yes/no) and if yes,
which type (insemination, ICSI/IVF). They were also asked
whether the semen was husband or donor provided and if they
had experienced any pregnancy-related complications, e.g.
bleeding during pregnancy (duration and extent) and pre-
eclampsia or pregnancy-induced hypertension. The intensity of
vaginal bleeding was classified by duration (#1 day/.1day) and
extent (spot bleeding/more than spot bleeding). Time to
pregnancy was defined at time period from cessation of use of
anti-conception. Furthermore, they were asked about daily
smoking habits (type, amount, duration) and changes in habits
during pregnancy (quit smoking (gestational week), reduced
smoking (gestational week), occasional smoking) and use of
substitutes in form of nicotine patches, spray or chewing gum
(duration, trimester) and exposure to passive smoking (daily
extent). Based on these questions the women were categorized
into different smoking categories (nonsmoker, current smoker, stop
of smoking before pregnancy/during pregnancy and occasional
smoker). Nonsmokers were defined as women who had never been
smoking in their entire life. Information on other maternal lifestyle
factors such as daily caffeine intake (cups of coffee and tea) and
weekly alcohol intake [21] were also obtained. The women also
reported self-experienced stress (yes/no). They were instructed to
complete the questionnaire at the beginning of the 3rd trimester
and to return it before birth. Data on pregnancy-related
complications such as pre-eclampsia and bleeding during preg-
nancy were also obtained from hospitals records at birth.
Social class was determined from self-reported occupational
status of the mother in seven hierarchical categories: higher-grade
professionals, lower-grade professionals, skilled workers, unskilled
workers, students, economically inactive and unclassifiable [22].
Simultanenously to the present cohort, but independent of it, a
national birth cohort study was conducted [Danish National Birth
Cohort (DNBC)] in Denmark [23]. The women participating in
DNBC answered two telephone interviews at around pregnancy
week 12 and 30, which contained most of the questions asked in
the self-adminstrered questionnaire used in our cohort. The
interviews and the questionnaire were developed in close
collaboration and therefore almost identical. In total, 495 Danish
women participated both in our study and in DNBC. Of these 210
women completed a shortened questionnaire to avoid unnecessary
repetition. The other 285 completed the entire questionnaire and
both interviews.
The study was conducted according to the Helsinki II
Declaration (http:/www.wma.net/e/policy/b3.htm) [24] and
was approved by the local ethical committees in both countries
(Finland: 7/1996, Denmark: KF01-030/97) and the Danish Data
Protection Agency (1997-1200-074, 2001-3311-0068).
Clinical examination
The boys were examined at birth and 3 months old. Preterm
born boys were examined at the expected date of delivery.
Gestational age was based on routine ultrasonography performed
in pregnancy week 18–20. If not available (2.1%), the last
menstrual period was used. Information on birth weight and parity
was obtained from birth records. Weight for gestational age
(WGA) was calculated according to national standards [25–27].
Repetitive workshops were held in order to ensure standardization
of the clinical procedures and to minimize inter-observer variation.
One Finnish doctor spent 1 year in Denmark allowing a close
harmonization of the examination techniques.
Definition of cryptorchidism and examination technique have
been described earlier [10]. The testis was considered cryptorchid,
if found in a high scrotal, supra-scrotal or inguinal position or if it
was non-palpable. Retractile testis was considered to be a normal
variant. The results presented in Tables 1–3 are based on the
diagnosis at the newborn examination, without sub-division to
cryptorchidism types.
Statistical analysis
Gestational age for completing questionnaires and interviews is
given as mean (standard deviation (SD)) and differences tested by
unpaired T-tests. Descriptive data of the mothers and the boys are
given as numbers and percentages (%). Differences between
cryptorchid boys and healthy boys were tested by Fischer’s exact
test (2-sided) or described by odds ratios (OR) and 95% confidence
intervals (95%CI). Odd ratios (unadjusted and adjusted) were
estimated using binary logistic regression. The covariates, which
were most closely associated with the investigated exposure and
cryptorchidism and factors which due to a priori knowledge from
other studies that they may influence the outcome, were included
as confounders in the analyses.
Validation study
Concerning smoking habits, a validation of comparability
between questionnaire and interview data, calculated in percent
of agreement, was performed among 285 Danish women, who
participated in both. Complete agreement in the answers
concerning smoking categories was found for 265 women (93%).
Minor disagreement was registered for 18 women (6%); 12 (4%)
women reported to have smoked occasionally during pregnancy in
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nonsmokers (n=7) or having stopped during pregnancy (n=5).
Six women (2%) who had quit smoking in early pregnancy
(questionnaire) were categorized as nonsmokers in the interview.
Major disagreement was found for 2 women (0.7%). One reported
smoking cessation before pregnancy in the questionnaire, but
answered to have stopped smoking while pregnant in the
interviews. One reported to be a smoker in the questionnaire,
but was registered as a nonsmoker in the interviews. The 285
women were included in the study with their questionnaire data.
Results
In Denmark, 1,042 boys (1,029 mothers) and in Finland 1,454
boys (1,446 mothers) participated in the study [21]. In total, 128
boys (94 Danish, 34 Finnish) were cryptorchid at birth, 33 (19
Danish, 14 Finnish) remained cryptorchid at the age of 3 months.
All interviews were conducted antenatally. Most questionnaires
(94%) were returned before birth. Return date was missing for 104
women [12 (9.4%) mothers of cryptorchid boys and 92 (3.9%)
mothers of normal boys, p=0.002]. Two mothers of cryptorchid
boys and 37 mothers of normal boys completed the questionnaire
after birth (p=0.687). Mean gestational age for completing of the
questionnaire/second interview for mothers of cryptorchid boys
was 199 days [standard deviation (SD) 41] versus 207 days (58) for
mothers of normal boys (p=0.211). The corresponding figures for
participating in the first interview were 113 days (33) and 115 days
(30), p=0.755.
Table 1 shows population characteristics. Cryptorchid boys had
an increased risk of hypospadias and twinning [odds ratios (OR)
3.74 and 2.30, respectively], however these differences were not
significant after adjustment for confounders. Low birth weight,
prematurity and being small for gestational age (SGA) were all
statistically significantly associated to cryptorchidism, also after
adjusting for confounders (OR 2.73, 2.14 and 2.55, respectively).
In total, 12 (9.4%) cryptorchid boys and 71 (3.0%) healthy boys
presented as breech at birth, a difference that remained significant
after adjustment. Stratified analyses showed that this difference
was statistically significant among mature boys (premature: OR
4.03 95%CI 0.71–22.94, mature OR 3.44 95%CI 1.46–8.13).
Caesarean section was more common among cryptorchid boys
(OR 1.83 95%CI 1.18–2.83), however, this difference did not
remain significant after adjusting. The odds ratios of cryptorchi-
dism according to parental characteristics are given in Table 2. No
significant differences were seen for maternal pre-pregnancy body
mass index (BMI). No effect of parental age was observed.
No increased risk of cryptorchidism among the offspring of
smokers was found (Table 2). Exposure to passive smoking had no
effect either (data not shown). Smoking mothers of cryptorchid
boys did not smoke significantly more cigarettes than smoking
mothers of healthy boys (n=294, mean 6.9 versus 5.8, p=0.458).
Heavy smokers, i.e. women smoking $10 cigarettes/day (n=64),
did not show an increased risk for having a cryptorchid boy
compared to nonsmokers (adjusted OR 0.59 95%CI 0.16–2.24).
Heavy smokers did not have significantly more boys with bilateral
cryptorchidism compared to nonsmokers (33.3% versus 24.1%,
Table 1. Population characteristics of 128 boys with congenital cryptorchidism and 2,368 healthy boys from a joint Danish-Finnish
birth cohort study.
Variable Subvariable Cryptorchid Healthy OR (95%CI) OR (95%CI)
n=128 n=2,368 Unadjusted Adjusted*
Hypospadias 2 (1.6) 10 (0.4) 3.74 (0.81–17.26) 1.08 (0.12–9.44)
Twinning 7 (5.5) 58 (2.4) 2.30 (1.03–5.16) 0.52 (0.19–1.47)
Birth weight (grams) ,2500 14 (10.9) 54 (2.3) 3.78 (1.98–7.20) 2.73 (1.14–6.55)
2500–3500 58 (45.3) 845 (35.7) 1 (ref) 1 (ref)
.3500 56 (43.8) 1,469 (62.0) 0.56 (0.38–0.81) 0.67 (0.44–1.04)
Maturity premature (,37 weeks) 18 (14.1) 103 (4.3) 3.58 (2.09–6.13) 2.14 (1.03–4.46)
mature (37–42 weeks) 105 (82.0) 2,152 (90.9) 1 (ref) 1 (ref)
postmature (.42 weeks) 5 (3.9) 113 (4.8) 0.91 (0.36–2.27) 0.99 (0.38–2.56)
Weight for gestational age (WGA)** SGA 8 (6.3) 57 (2.4) 2.75 (1.28–5.89) 2.55 (1.06–6.13)
AGA 115 (89.8) 2,251 (95.1) 1 (ref) 1 (ref)
LGA 5 (3.9) 60 (2.5) 1.63 (0.64–4.14) 2.04 (0.77–5.39)
Parity 1 79 (61.7) 1,369 (57.8) 1 (ref) 1 (ref)
2 34 (26.6) 700 (29.6) 0.84 (0.56–1.27) 1.15 (0.71–1.85)
$3 15 (11.7) 299 (12.6) 0.87 (0.49–1.53) 1.28 (0.64–2.59)
Presentation Head 115 (90.6) 2,277 (96.4) 1 (ref) 1 (ref)
Breech 12 (9.4) 71 (3.0) 3.35 (1.77–6.35) 2.59 (1.12–5.97)
Other 0 14 (0.6) - -
Delivery Vaginal 83 (64.8) 1,787 (75.5) 1 (ref) 1 (ref)
Vacuum 16 (12.5) 239 (10.1) 1.44 (0.83–2.50) 1.54 (0.84–2.83)
Caesarean section 29 (22.7) 342 (14.4) 1.83 (1.18–2.83) 1.04 (0.57–1.89)
Values are given as numbers (n) and percentages (%).
*All variables adjusted for country, maternal age, smoking, alcohol consumption and social class. Furthermore, adjusted for parity, twinning, mode of delivery,
presentation, birth weight (except WGA) and gestational age (except WGA), mutually.
**SGA: small for gestational age, AGA: appropriate for gestational age, LGA: large for gestational age.
doi:10.1371/journal.pone.0003051.t001
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pregnant (n=379) reported to have smoked $10 prior to
cessation. Including these women in the analyses as heavy smokers
did not change the results (data not shown). Smoking cessation was
most common in the first trimester (n=323, 85%), whereas 12%
and 3% reported to have stopped during the 2nd and 3rd
trimester, respectively.
Users of nicotine substitutes (n=40) (disregarding their current
smoking habits) had an increased risk of cryptorchidism in their
offspring (OR 3.04 95%CI 1.00–9.27). Both women who ceased
smoking during pregnancy (n=20) and used substitutes (OR 4.60
95%CI 1.10–19.23), and women who continued smoking
throughout the entire pregnancy (n=16) and used substitutes
had increased odds (OR 2.42, 95%CI 0.46–12.70), albeit
statistically significance was not reached for the latter. Four
women who stopped smoking before pregnancy used nicotine
substitutes during pregnancy (all healthy sons).
Compared to nonsmokers, substitute users were older, more
often reported to have been dis-stressed during pregnancy,
belonging to social class 1 or 2 and had a smaller weekly alcohol
intake, a higher daily intake of tea and coffee, whereas no
differences were seen in birth weight, parity or gestational age
(data not shown). Mothers who used nicotine substitutes did tend
to smoke more cigarettes per day than women who did not use
substitutes (mean 9.6 versus 6.2, respectively p=0.010). Exclusion
of heavy smokers ($10 cigarettes per day) from the analyses did
not change the results (data not shown). Information on type of
nicotine substitute was available for 5 of 6 mothers giving birth to
cryptorchid boys and for 30 out of 34 mothers giving birth to
normal boys. Self-reported maternal stress during the last 6
months was associated with cryptorchidism (OR 1.79 95%CI
1.17–2.74), although the association was not significant after
adjustment (OR 1.34 95%CI 0.85–2.12). Table 3 shows
pregnancy-related complications. An increased risk for cryptor-
chidism was found among mothers who reported pre-eclampsia/
pregnancy-induced hypertension or vaginal bleeding. After
adjusting the difference remained statistically significant only for
substantial vaginal bleeding (OR 2.23, 95%CI 1.06–4.69).
No difference in time to pregnancy was found between mothers
to healthy and cryptorchid boys. Significantly more mothers to
cryptorchid boys had been treated with intrauterine insemination
(OR 3.01 95%CI 1.27–7.15). Semen originated from the father
among 45 boys (7 cryptorchid sons, 38 healthy sons) and from a
donor among 4 boys (all healthy). Mothers who had intrauterine
Table 2. Parental characteristics of 128 boys with congenital cryptorchidism and 2,368 healthy boys in a joint Danish-Finnish birth
cohort study.
Cryptorchid Healthy OR (95%CI) OR (95%CI)
n=128 n=2,368 Unadjusted Adjusted
*
Maternal pre-pregnancy BMI
,20 20 (16.3) 398 (17.1) 0.97 (0.58–1.60) 0.91 (0.53–1.57)
20–25 71 (57.7) 1,363 (58.7) 1 (ref) 1 (ref)
.25 32 (26.0) 561 (24.2) 1.10 (0.71–1.68) 1.14 (0.72–1.80)
Maternal social class
1+2:higher and low grade professionals 46 (39.0) 808 (36.7) 1 (ref) 1 (ref)
3+4:skilled and unskilled workers 51 (43.2) 1,071 (48.7) 0.84 (0.56–1.26) 1.00 (0.66–1.52)
5+6:students and economically inactive 21 (17.8) 322 (14.6) 1.15 (0.67–1.95) 1.15 (0.67–1.96)
Maternal age (years)
,30 62 (48.4) 1,231 (52.0) 1 (ref) 1 (ref)
$30 66 (51.6) 1,137 (48.0) 1.15 (0.81–1.65) 0.95 (0.64–1.40)
Paternal age (years)
,30 35 (33.3) 846 (39.3) 1 (ref) 1 (ref)
$30 70 (66.7) 1,307 (60.7) 1.30 (0.86–1.96) 1.05 (0.68–1.62)
Maternal smoking
Smoking categories
0: nonsmoker
** 58 (45.7) 1,172 (49.5) 1 (ref) 1 (ref)
***
1: cessation before pregnancy 31 (24.4) 506 (21.4) 1.24 (0.79–1.94) 1.05 (0.61–1.80)
2: occasional smoker 1 (0.8) 44 (1.9) 0.46 (0.06–3.39) -
3: cessation during pregnancy 19 (15.0) 360 (15.2) 1.07 (0.63–1.81) 0.87 (0.43–1.76)
4: current smoker 18 (14.2) 286 (12.1) 1.27 (0.74–2.19) 0.90 (0.43–1.87)
Smoking substitute
nonsmoker 58 (45.7) 1,172 (49.5) 1 (ref) 1 (ref)
***
smoking categories 1–42substitutes 63 (49.6) 1,162 (49.1) 1.10 (0.76–1.58) 0.84 (0.53–1.33)
smoking categories 1–4+substitutes 6 (4.7) 34 (1.4) 3.57 (1.44–8.83) 3.04 (1.00–9.27)
Values are given as numbers (n) and percentages (%).
*Adjusted for country and social class.
**Nonsmoker: woman who has never been smoking in her entire life.
***Adjusted for country, social class, birth weight, stress, alcohol and caffeine intake.
doi:10.1371/journal.pone.0003051.t002
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to pregnancy (TTP) and more were from social class 1 or 2 than
mothers who did not have any infertility treatment (data not
shown). No association was seen for mothers who had infertility
treatment in form of intracytoplasmic sperm injection (ICSI) or in
vitro fertilization (IVF) treatment (OR 0.71, 95%CI 0.21–2.38).
Information on infertility treatment was missing for 16 (12.5%)
mothers of cryptorchid boys and for 229 (9.7%) mothers of normal
boys, p=0.295. Including missing data concerning infertility
treatment as having no infertility treatment did not change the
results [adjusted OR (95%CI) for insemination and ICSI/IVF
treatment 3.13 (1.32–7.41) and 0.75 (0.23–2.52), respectively].
Analysis of boys who remained cryptorchid at 3 months of age
showed comparable results to boys with cryptorchidism at birth
(data not shown), which however, did not reach statistical
significance due to the small group size (n=33).
Discussion
In this prospective study of risk factors for cryptorchidism, we
found that significantly more mothers of cryptorchid boys had
been treated with intrauterine insemination and used nicotine
substitutes than mothers of normal boys, which to our knowledge
has not been described before. However, no increased risk among
mothers treated with IVF/ICSI was observed.
No detailed information about the infertility treatment regime
or the number of treatments was obtained. However, in both
countries the majority of intrauterine insemination treatment will
include clomiphene citrate administered orally, which exhibits
both estrogenic and anti-estrogenic activity [28]. The half-life of
clomiphene is up to 1 month, and it may accumulate over
consecutive cycles of treatment [29]. It is therefore biologically
plausible that the fetus could have been exposed to this compound
during the critical stages of development in the first trimester.
Animal studies have reported that clomiphene administration
shortly after birth to male rats had long-term adverse effects on the
reproductive physiology and sexual behaviour [30,31]. Adverse
effects such as epithelium changes on the developing female
reproductive tract in humans exposed antenatally to tamoxifen or
clomiphene, resembling those seen after prenatal diethylstilbestrol
exposure, have also been reported [32]. The effects of clomiphene
on the developing reproductive tract in human males have been
reported in a few studies. Berkowitz et al found that clomiphene
use before conception was associated with a 2-fold increase in risk
of cryptorchidism, which however did not reach statistical
significance [13]. One study indicated that clomiphene treatment
of the mother was associated with penoscrotal hypospadias in the
male offspring [33]. In addition, other exogenous hormonal
treatments, especially diethylstilbestrol, but also hormonal contra-
ception and hormonal pregnancy tests have previously been found
to be associated with an increased risk of congenital malforma-
tions, including cryptorchidism [18,34,35,36–41].
Surprisingly, we found no adverse effect of ICSI/IVF treatment
on the risk of cryptorchidism. This may be explained by a different
hormonal treatment regimen, consisting of initial suppression of
the pituitary axis with a gonadotropin releasing hormone
analogue, followed by follicle stimulating hormone, human
menopausal gonadotropin and in some cases recombinant human
luteinizing hormone. In general the half-life of these compounds is
shorter than that of clomiphene. Previous registry studies of birth
defects among children conceived after ICSI/IVF have found an
increased risk for hypospadias, but not for cryptorchidism [42,43].
As expected, mothers who had insemination treatment were
older, had a lower parity, a longer waiting time to pregnancy
(TTP) and more were from social class 1 or 2 than mothers who
did not have infertility treatment. Thus, parental subfertility per se
Table 3. Number of planned pregnancies, time to pregnancy, infertility treatment and pregnancy related complications in a joint
Danish-Finnish birth cohort study.
Variable Subvariable Cryptorchid Healthy OR (95%CI) OR (95%CI)
n=128 n=2,368 Unadjusted Adjusted
*
Pregnancy planned yes/partly 111 (88.8) 2,119 (90.4) 1 (ref) 1 (ref)
Pregnancy planned no 14 (11.2) 225 (9.6) 1.19 (0.67–2.11) 0.90 (0.49–1.67)
Time to pregnancy
** ,4 65 (72.2) 1,206 (63.1) 1 (ref) 1 (ref)
Time to pregnancy
** 4–12 12 (13.3) 384 (20.1) 0.58 (0.31–1.09) 0.60 (0.32–1.14)
.12 13 (14.4) 320 (16.8) 0.75 (0.41–1.39) 0.70 (0.36–1.35)
Infertility treatment none 102 (91.1) 2,021 (94.5) 1 (ref) 1 (ref)
Infertility treatment insemination 7 (6.3) 42 (2.0) 3.30 (1.45–7.53) 3.01 (1.27–7.15)
ICSI/IVF 3 (2.7) 76 (3.6) 0.78 (0.24–2.52) 0.71 (0.21–2.38)
Nausea no 45 (36.9) 802 (34.6) 1 (ref) 1 (ref)
Nausea yes 77 (63.1) 1,517 (65.4) 0.91 (0.62–1.32) 0.87 (0.58–1.30)
Vomiting no 78 (72.2) 1,473 (66.8) 1 (ref) 1 (ref)
Vomiting yes 30 (27.8) 733 (33.2) 0.77 (0.50–1.19) 0.81 (0.52–1.26)
Pre-eclampsia or hypertension no 84 (90.3) 1,933 (95.3) 1 (ref) 1 (ref)
Pre-eclampsia or hypertension yes 9 (9.7) 95 (4.7) 2.18 (1.06–4.47) 1.72 (0.79–3.75)
Substantial bleeding no 118 (92.9) 2,269 (97.0) 1 (ref) 1 (ref)
Substantial bleeding yes 9 (7.1) 69 (3.0) 2.51 (1.22–5.15) 2.23 (1.06–4.69)
Values are given as numbers (n) and percents (%).
*Adjusted for country, maternal age, social class and parity.
**Time to pregnancy from cessation use of anti-conception.
doi:10.1371/journal.pone.0003051.t003
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in couples treated with ICSI and IVF resemble those treated with
insemination as to age, parity, TTP and social class, but these
treatments are used in more severe cases of infertility and male
factor infertility (ICSI). The percentages of mothers receiving
infertility treatment in our cohort resemble those of the general
Danish population [44]. We found no increased risk for
cryptorchidism among subfertile women (with a long TTP) who
did not receive treatment.
We did not find any association between maternal smoking and
cryptorchidism, which is supported by most previous studies
[7,13,16,45,46]. One recent study has, however, found that heavy
maternal smoking ($10 cigarettes/day, registered retrospectively)
increased the risk of bilateral cryptorchidism [47]. In our study,
heavy smokers did not have an increased risk of having a
cryptorchid boy compared to nonsmokers and the distribution of
bilateral versus unilateral cryptorchidism did not differ signifi-
cantly either. However, we found that mothers who used nicotine
substitutes had a significantly increased risk of having a
cryptorchid son. A recent publication reported that children born
to mothers who used nicotine substitutes during the first trimester
had a slightly increased risk of congenital malformations,
particularly musculoskeletal defects [48]. It should be noted that
this study only examined the use of substitutes in the first 12 weeks
of pregnancy in women who had stopped smoking before
pregnancy. In our study both women who stopped smoking
during pregnancy and women who continued smoking despite
simultaneous use of substitutes were included. The group of
women who stopped smoking before pregnancy but still used
nicotine substitutes during pregnancy was too small (n=4) to make
separate analyses and the two studies are therefore not exactly
comparable. We do not know if substitute users who quit smoking
while pregnant, stopped smoking before or at the same time as
they started to use substitutes or if they both smoked and used
substitutes for a period. No information on precise amount or
doses and the precise duration of the use of the substitutes was
obtained. Women who used substitutes tended to smoke more
than women who did not use substitutes, which would be
expected. However, we do not believe that the effect seen of
using substitutes could be explained by this difference, as
comparable results were found when heavy smokers were excluded
from the analyses. Obvious confounders such as alcohol and
coffee/tea consumption did not affect our results, but we cannot
exclude the association to be confounded by other lifestyle factors
not analyzed in our study, e.g. diet. Our findings need to be
confirmed in larger groups of women who smoke and use nicotine
substitutes. It may not be nicotine per se that constitutes the risk
factor, but other chemical substances in the delivery devices that
women are exposed to concomitantly.
In accordance with many previous studies low birth weight,
prematurity and being small for gestational age were independent
risk factors of cryptorchidism [8,12,13,46]. As in some previous
studies [19,39,46,49], we found associations between caesarean
section, breech presentation and cryptorchidism. However, after
adjusting caesarean section was no longer significant risk factor,
which indicates that caesarean section reflects other risk factors
such as prematurity, low birth weight and/or abnormal presen-
tation. Although breech delivery per se has been shown to be
associated with testicular damage, it is unlikely that the observed
association is due to mechanical factors alone, as most of these
boys in our study were delivered by cesarean section. Breech
presentation may therefore be a marker for a maternal or fetal
characteristics associated with cryptorchidism, e.g. placental
impairment such as placenta praevia or low placenta weight [50].
Mothers with substantial bleeding during pregnancy had a
significantly increased risk of having a cryptorchid boy. Vaginal
bleedingmay beanindicatorof placentamalfunction,whichinturn,
may affect human choriogonadotropin (hCG) production and
stimulation of testicular hormonal synthesis. Previously published
studies on vaginal bleeding show conflicting results [7,13,16,18].
High maternal BMI, vomiting and nausea, low parity, twinning and
young maternal age are risk factors considered to indicate high
endogenous maternal estrogen levels [51], but previous data are not
consistent. [6,7,17,49]. We were not able to detect any associations
to these risk factors, which may be caused by the fact that our
prospective cohort included relatively few mothers who exhibited
these risk factors. An apparent increased risk for twins disappeared
after adjusting for relevant confounders, e.g. low birth weight, which
is in accordance to other studies [8]. Only few mother had a high
BMI and our study may therefore be too small to detect an adverse
effect of maternal BMI.
We conducted our study as a prospective cohort, in which
information on maternal exposure were collected before birth in
order to minimise recall-bias, which strengthens our findings.
Furthermore, all the children were examined by trained observers
who participated in repetitive workshops in order to ensure a valid
diagnosis. Most mothers completed the questionnaire in the 3rd
trimester and the range of gestational age for completing the
questionnaire did not differ between cryptorchid and normal boys.
Only 22–24% of all eligible women participated in our study and
mothers with an academic degree were over-represented. Our
findings are therefore not representative of the entire Danish and
Finnish population. However, this should not bias our estimates of
the association between potential risk factors and cryptorchidism, as
the data was collected prospectively and therefore any misclassifi-
cation of exposure and outcome was most likely to be non-
differential, causing a bias toward the null hypothesis. Furthermore,
the cohort design also minimized the risk of selection bias among the
healthy boys. Finally, in Finland, the entire hospital birth cohort was
followed in the same period, and its cryptorchidism prevalence was
similar tothat of this prospectivecohort, suggesting that there was no
selection bias [10]. The limitation of the prospective design is the
relative small number of cases resulting in many non-significant
results after adjustment for confounders.
Validation revealed a very good agreement in reporting smoking
habitsbyinterviewandquestionnaire,andwedonotbelievethatthis
may have introduced bias. Furthermore, sensitivity analyses
including missing values did not change the overall results. The
study examined association with many risk factors, and some of the
reported findings may therefore be spurious due to multiple testing.
However,the associationwithseveralpreviouslyreported riskfactors
for cryptorchidism were confirmed.
In our study, most boys with congenital cryptorchidism showed
spontaneous descent after birth. Thus, our group of cryptorchid boys
is notdirectlycomparable tostudies including, e.g. childrenscheduled
for orchidopexy, who have persistent cryptorchidism. We have
previously shown, that these transient and usually mild cases of
cryptorchidism also show signs of subtle impairment of testicular
function at three months of age [52]. The geographical difference in
the prevalence of cryptorchidism between Denmark and Finland and
the increase in the Danish prevalence is mostly due to this type of
cryptorchidism [10]. Thus, lifestyle factors may in particular be
involved in the aetiology of mild types of cryptorchidism.
In conclusion, we found that intrauterine insemination and the
use of nicotine substitutes were associated with an increased risk of
having a boy with cryptorchidism. This suggests that maternal
lifestyle factors and exposures play a role for testicular descent in
humans. During the last decades infertility treatment has become
Risk Factors for Cryptorchidism
PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e3051an increasing part of the health care system [44]. Likewise, an
increased public awareness for the adverse effects of smoking
during pregnancy may encourage an increasing number of women
to quit smoking, some of which with the aid of nicotine substitutes
[53]. The above-mentioned factors may thus be contributing to
the increased prevalence of congenital cryptorchidism, which
warrants further studies.
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